Good morning, 360!
A special invitation to join Jeff Williams TONIGHT at 7pm EST for a complimentary options training class. Bring your pencil and your questions and join him tonight in THIS ROOM (compliments of JW).
FOCUS LIST🔎
CTXR – Up over 25% in the pre-market after Phase 3 trial success
AULT – Up over 30% in pre after reporting earnings, 55% revenue increase
LRMR – Up over 20% in pre after FDA removes partial clinical hold
*sponsored by Shore Thing Media
Coming fresh off an amazing 40% runner yesterday (which we still think is in play, so keep your eyes on it), here’s another potential “bottom bounce” play that looks enticing.
Go to your favorite platform and pull up Xylo Technologies (XYLO).
You can see this “bottom bounce” pattern – when a small stock drops in price, finds a bottom (for at least a few days), and then starts to rebound from the lows.
See the big drop that happened a few weeks ago in the chart below?
Then, look at how the stock had a “basing pattern” for several days afterward.
Now, you can see the last few days, XYLO has been stealthily creeping higher.
For price levels, I always look for a closing price under the area where the “base” occurred (the area above I circled).
If that breaks again, I’d have to say the bounce didn’t work, and it would be time for me to move to the sidelines.
However, if things go well, the first area of resistance I would look at would be the $2.50 – $2.75 spot. You can see that was where the stock traded for most of March and April.
From today’s price, that would be a roughly 20% move higher if XYLO can get back to that level.
If XYLO can manage to break past that, I think it could really fly ✈️
I’m not at all saying that will happen, but it can give you a range of possibilities if things work out perfectly.
While I think it is a great-looking setup, it’s important you dig into the details of what the company does and make sure to do your own research, as trading is risky and nothing is guaranteed.
See our full report and keep XYLO on top of your trading radar!
*Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results.
HOTLIST🔥
CTXR – Up over 25% in the pre-market after Phase 3 trial success
Citius Pharmaceuticals Inc. (CTXR) is a late-stage pharmaceutical company that engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy.
In the pre-market this morning the company announced that it had met the primary and secondary Endpoints in its Phase 3 Trial of Mino-Lok Antibiotic Lock Solution.
Mino-Lok®, a novel antibiotic lock solution designed to salvage catheters in patients with central line-associated infections (CLABSI) or catheter-related bloodstream infections (CRBSI).
The study met its primary endpoint with a statistically significant improvement in the time to failure event in patients receiving Mino-Lok compared to Control arm patients receiving clinician-directed anti-infective lock solution. The data demonstrate that Mino-Lok is well-tolerated.
Leonard Mazur, Chairman and Chief Executive Officer of Citius stated
“We believe Mino-Lok could potentially set a new standard of care (SOC) as an adjunct therapy in the treatment of patients with bloodstream infections. This therapy offers a non-invasive treatment option compared to catheter removal and replacement”
The stock traded up over 25% in the pre-market in reaction to the positive Phase 3 trial results.
$0.75 has acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $0.87, $0.85, $1 and then the pre-market high at $1.09. Beyond that $1.20, $1.30 and $1.40 come into play.
Below $0.75 targets to the downside are $0.72 and then a gap fill at $0.6598.
AULT – Up over 30% in pre after reporting earnings, 55% revenue increase
Ault Alliance Inc. (AULT) provides customized solutions for the military markets in North America and internationally. It operates through eight segments: Energy and Infrastructure, Technology and Finance, SMC, Sentinum, GIGA, TurnOnGreen, ROI, and Ault Disruptive.
In the after-hours yesterday, the company reported Q1 2024 financial results.
Highlights include:
Revenue from digital assets mining increased 56% to $11.4 million, compared to $7.3 million in the prior year’s first fiscal quarter;
Revenue from lending and trading activities increased to $9.1 million, compared to negative $4.9 million in the prior year’s first fiscal quarter;
Gross margins improved to 43%, compared to 9% in the prior year’s first fiscal quarter;
Operating expenses declined 41% to $19.1 million, compared to $32.3 million in the prior year’s first fiscal quarter;
Income from operations improved to $0.4 million, compared to a loss from operations of $29.9 million in the prior year’s first fiscal quarter;
Total assets of $299.8 million as of March 31, 2024; and
Net income available to common stockholders of $2.5 million, compared to a net loss available to common stockholders of $48.9 million in the prior year first fiscal quarter.
The stock traded up over 20% in the pre-market in reaction to the financial results.
The first target for bulls is the pre-market high at $0.58.
Beyond that, $0.60, $0.80 and $1 come into play.
Below $0.58, targets to the downside are $0.52, $0.50, $0.44 and then a gap fill at $0.3924.
LRMR – Up over 20% in pre after FDA removes partial clinical hold
Larimar Therapeutics Inc. (LRMR) is a clinical-stage biotechnology company that focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.
In the after-hours yesterday, the company announced that the FDA had removed its partial clinical hold for the Nomlabofusp program in Friedreich’s Ataxia.
Nomlabofusp is a novel protein replacement therapy designed to address the root cause of FA by delivering frataxin to mitochondria.
The FDA removed the partial clinical hold after a review of data from the Company’s recently completed four-week, placebo-controlled Phase 2 dose exploration study.
The review included data from both the 25 mg and 50 mg cohorts in patients who received daily dosing of Nomlabofusp for 14 days followed by every other day dosing until day 28.
LRMR’s interim data from OLE study remains on track for Q4 2024
It’s Biologics License Application (BLA) submission targeted for 2H 2025.
The stock traded up over 20% in the pre-market in reaction to the positive news.
The $8.35 area has acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $9, $9.80 and then the after-hours high at $10.68. Beyond that, $11.50, $12 and $13 come into play.
Below $8.35, targets to the downside are $8, $7.50 and then a gap fill at $7.27.
MARKET NEWS 📰
👊 Make sure you are getting my mobile text alerts – text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas. Don’t miss out!
Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull
*Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”
Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received seventeen thousand five hundred dollars (cash) from Shore Thing Media for advertising Xylo Technologies Ltd for a one day marketing program on may 21, 2024. This amount was paid by someone else not connected to Xylo Technologies Ltd. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.
Now, diving right into Xylo Technologies Ltd might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.
Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.
Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear,
Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization.
So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.
